Cancer Genetics, Inc. develops, commercializes, and provides molecular and biomarker-based tests and services in the United States, Europe, and Asia. Its tests enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor, and inform cancer treatment; and enable biotech and pharmaceutical companies involved in oncology and immuno-oncology trials to select candidate populations and reduce adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics. The company's biopharma services offer companies with customized solutions for patient stratification and treatment selection through a suite of molecular- and biomarker-based testing services, customized assay development, and trial design consultation. Its clinical services provide information on diagnosis, prognosis, and predicting treatment outcomes of cancers to guide patient management. The company's discovery services offer the tools and testing methods for companies and researchers to identify and develop new compounds and molecular-based biomarkers for diagnostics and treatment of disease. It serves hospitals, cancer centers, clinics, academic institutions, and government-sponsored research institutions, as well as pharmaceutical and biotech companies performing clinical trials. The company collaborates with oncology centers and community-based hospitals to develop its proprietary diagnostic tests. Cancer Genetics, Inc. was founded in 1999 and is based in Rutherford, New Jersey.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CGIX
CUSIPN/A
Phone201-528-9200
Debt
Debt-to-Equity Ratio0.03
Current Ratio0.92
Quick Ratio0.92
Price-To-Earnings
Trailing P/E Ratio-1.36
Forward P/E Ratio-2.24
P/E GrowthN/A
Sales & Book Value
Annual Sales$29.12 million
Price / Sales1.05
Cash FlowN/A
Price / CashN/A
Book Value$0.97 per share
Price / Book1.13
Profitability
EPS (Most Recent Fiscal Year)($0.79)
Net Income$-20,880,000.00
Net Margins-52.87%
Return on Equity-77.26%
Return on Assets-38.54%
Miscellaneous
Employees245
Outstanding Shares27,750,000
Market Cap$26.22 million
Cancer Genetics (NASDAQ:CGIX) Frequently Asked Questions
What is Cancer Genetics' stock symbol?
Cancer Genetics trades on the NASDAQ under the ticker symbol "CGIX."
How were Cancer Genetics' earnings last quarter?
Cancer Genetics Inc (NASDAQ:CGIX) issued its quarterly earnings results on Tuesday, August, 14th. The medical research company reported ($0.13) EPS for the quarter, topping the Zacks' consensus estimate of ($0.16) by $0.03. The medical research company had revenue of $7.04 million for the quarter, compared to analyst estimates of $8.80 million. Cancer Genetics had a negative return on equity of 77.26% and a negative net margin of 52.87%. View Cancer Genetics' Earnings History.
When is Cancer Genetics' next earnings date?
What price target have analysts set for CGIX?
3 brokerages have issued 1 year price objectives for Cancer Genetics' stock. Their predictions range from $3.00 to $6.00. On average, they anticipate Cancer Genetics' share price to reach $4.50 in the next twelve months. This suggests a possible upside of 320.6% from the stock's current price. View Analyst Price Targets for Cancer Genetics.
What is the consensus analysts' recommendation for Cancer Genetics?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cancer Genetics in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Cancer Genetics.
What are Wall Street analysts saying about Cancer Genetics stock?
Here are some recent quotes from research analysts about Cancer Genetics stock:
- 1. Maxim Group analysts commented, "Cancer Genetics reported revenue of $7.0M, down sequentially (8%) and a net loss of $3.6M. CGIX ended the period with $1.6M in cash, excluding $2.5M raised in July. We expect the company to raise more capital to continue its restructuring efforts. Key takeaway: While revenue is down, management is continuing to make progress implementing the restructuring strategy that we believe over time should position CGIX to streamline its cancer testing, biopharma and discovery business and return the company to growth. As such, 2018 should be viewed as a transition year for CGIX. We maintain a Hold rating." (8/14/2018)
- 2. According to Zacks Investment Research, "Cancer Genetics, Inc. operates as a diagnostics company focused on developing and commercializing proprietary genomic tests and services to improve the diagnosis, prognosis and response to treatment of cancer. The company's tests target cancers, including hematological, urogenital, and HPV-associated cancers. It also offers non-proprietary oncology-focused tests and laboratory services that provide critical genomic information to healthcare professionals as well as biopharma and biotech. Cancer Genetics, Inc. is headquartered in Rutherford, New Jersey. " (7/3/2018)
Who are some of Cancer Genetics' key competitors?
Who are Cancer Genetics' key executives?
Cancer Genetics' management team includes the folowing people:
- Mr. John A. Roberts, Pres, CEO, COO & Director (Age 59)
- Dr. Rita Shaknovich, Chief Medical Officer & Group Medical Director (Age 50)
- Mr. Igor Gitelman CPA, MBA, Chief Accounting Officer (Age 42)
- Mr. Michael Brian McCartney, Chief Commercial Officer
- Dr. Ralf Brandt, Pres of Discovery & Early Devel. Services (Age 55)
Has Cancer Genetics been receiving favorable news coverage?
News headlines about CGIX stock have trended somewhat positive this week, according to Accern. The research group ranks the sentiment of media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Cancer Genetics earned a news impact score of 0.18 on Accern's scale. They also gave news headlines about the medical research company an impact score of 46.32 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near term. View Recent Headlines for Cancer Genetics.
Who are Cancer Genetics' major shareholders?
Cancer Genetics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Stonepine Capital Management LLC (5.01%) and Renaissance Technologies LLC (2.12%). Company insiders that own Cancer Genetics stock include Edward J Sitar, Geoffrey E Harris, Igor Gitelman, John A Roberts and John Pappajohn. View Institutional Ownership Trends for Cancer Genetics.
Which institutional investors are selling Cancer Genetics stock?
Which institutional investors are buying Cancer Genetics stock?
CGIX stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. Company insiders that have bought Cancer Genetics stock in the last two years include Geoffrey E Harris, Igor Gitelman, John A Roberts and John Pappajohn. View Insider Buying and Selling for Cancer Genetics.
How do I buy shares of Cancer Genetics?
Shares of CGIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cancer Genetics' stock price today?
One share of CGIX stock can currently be purchased for approximately $1.07.
How big of a company is Cancer Genetics?
Cancer Genetics has a market capitalization of $26.22 million and generates $29.12 million in revenue each year. The medical research company earns $-20,880,000.00 in net income (profit) each year or ($0.79) on an earnings per share basis. Cancer Genetics employs 245 workers across the globe.
How can I contact Cancer Genetics?
Cancer Genetics' mailing address is 201 ROUTE 17 NORTH 2ND FLOOR, RUTHERFORD NJ, 07070. The medical research company can be reached via phone at 201-528-9200 or via email at [email protected]
MarketBeat Community Rating for Cancer Genetics (NASDAQ CGIX)
MarketBeat's community ratings are surveys of what our community members think about Cancer Genetics and other stocks. Vote "Outperform" if you believe CGIX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CGIX will underperform the S&P 500 over the long term. You may vote once every thirty days.
